Chronic hepatitis C: management in primary care
Review your diagnosis, pretreatment assessment, and use of medical tests and medicines for your patients with chronic hepatitis C virus (HCV) infection, and increase your confidence in providing frontline primary health care for patients affected by this major public health issue.
Attendance at an NPS MedicineWise small group meeting 'Chronic hepatitis C in general practice' is a prerequisite for this Clinical e-Audit.
Data for only FIVE (5) patients is required. If you received a MedicineInsight report with your individual practice’s data, use the patient list that was made available to you after the small group meeting. Otherwise see Appendix 1 for instructions to identify patients with chronic hepatitis C in your clinical information system.
This program is funded by Gilead Sciences Pty Ltd and managed through VentureWise, a wholly owned commercial subsidiary of NPS MedicineWise. The program has been designed, developed and implemented by NPS MedicineWise with complete independence and editorial control and is based on best practice guidelines.
This activity has been accredited for 40 (Category 1) points (QI activity) in the RACGP QI&CPD Program for the 2017-2019 triennium (160197)
This activity has been accredited for 30 PRPD points in the ACRRM PDP Program for the 2017-2019 triennium (16817)
182,283 people in Australia were living with chronic HCV infection at the end of 2017. Infection with HCV increases the risk of progressive liver fibrosis which can lead to cirrhosis, hepatocellular carcinoma and liver failure. In 2017, approximately 95% of those who were treated were cured, yet only 11% of people living with chronic HCV infection received treatment during that year. GPs in primary care play a key role in identifying people for treatment, assessing for co-infection and liver disease, and helping patients manage the infection.
Our Clinical e-Audits are free quality improvement activities that help GPs review their current prescribing practice and overall management for patients with certain conditions, compared with current best practice guidelines.
- completing electronic data collection for 5 patients
- submitting de-identified data securely online
- reflecting on immediate patient-specific feedback to assist implementation of changes to practice
- reviewing individual and peer feedback results, based on achievement of best practice clinical indicators
- recording progress of individual patients automatically identified for review
- reflecting on improvements in your practice.
Participation in this activity will help you to:
- Recognise the tests required to confirm diagnosis and assess for co-existing conditions to guide treatment of chronic hepatitis C infection
- Identify patients for treatment and recognise patient and medicine factors that affect treatment selection and efficacy
- Verify treatment success at 12 weeks post-treatment
- Distinguish between the different options for assessing liver disease in patients with chronic hepatitis C infection.
- have access to a summary of best practice recommendations
- receive practical advice to provide to your patients
- create an individualised management plan for each patient
- receive immediate feedback and be able to compare your results with those of your peers.
Expert commentary by Dr Anne Balcomb
Dr Anne Balcomb is a rural GP based in Orange, NSW, who has been involved in treating chronic hepatitis C since 2008. She was instrumental in re-establishing a hepatitis C service in collaboration with local gastroenterologists, based in an opiate-replacement setting where all patients were triaged prior to interferon-free regimens. Anne is passionate about supporting and upskilling general practitioners across the region to treat viral hepatitis.